Vyteris has received a grant of $489,000 under the US Government's Qualifying Therapeutic Discovery Project (QTDP) program, for the development of its proprietary active transdermal smart patch technology.
Vyteris is the maker of the first active, ready-to-use drug delivery patch (LidoSite) to receive marketing clearance from the US Food and Drug Administration.
Vyteris said that the QTDP grants will be used to advance the company’s smart patch technology for the delivery of therapeutic medicines planned for use to treat female infertility and diabetes.
The QTDP program was created by the US Congress as part of the Patient Protection and Affordable Care Act passed on 23 March 2010.
Vyteris CEO Haro Hartounian said that the grant furthers the development of Vyteris’ active transdermal technology.
“Federal government support is an essential piece of our short term financing strategies to further our programs,” Hartounian said.